SCHEMBL345773

SCHEMBL345773

COC(=O)C1CCc2cc(NC(=O)C3(C)CCN(C(=O)OC(C)(C)C)CC3)ccc2C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
PTPN1 P18031 2/20 0.44
PTPN2 P17706 1/20 0.44
PTPN6 P29350 1/20 0.44
ALDH1A1 P00352 2/20 0.43
GPR119 Q8TDV5 7/20 0.42
STS P08842 1/20 0.40
ABL1 P00519 1/20 0.40
RIN1 Q13671 1/20 0.40
NAMPT P43490 1/20 0.39
NOD2 Q9HC29 1/20 0.39
NOD1 Q9Y239 1/20 0.39
NTRK1 P04629 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ESR2 Q92731 1/20 0.39
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL346653 0.96 NPC1 (0.56) NPC1RAB9APTPN1PTPN2PTPN6
SCHEMBL345519 0.91 NPC1 (0.58) NPC1RAB9APTPN1PTPN2PTPN6
SCHEMBL346486 0.87 NPC1 (0.58) NPC1RAB9APTPN1PTPN2PTPN6
SCHEMBL31058077 0.76 NAMPT (0.59) NPC1RAB9APTPN1PTPN2PTPN6
SCHEMBL346340 0.75 NPC1 (0.52) NPC1RAB9AALDH1A1NAMPTMEN1
SCHEMBL346828 0.74 NPC1 (0.49) NPC1RAB9APTPN1
SCHEMBL8414400 0.74 NPC1 (0.49) NPC1RAB9APTPN1PTPN2PTPN6
SCHEMBL20137661 0.74 TSHR (0.52) PTPN1PTPN2PTPN6ALDH1A1GPR119
SCHEMBL438223 0.74 NPC1 (0.41) NPC1RAB9AALDH1A1KMT2A
SCHEMBL31058055 0.73 PTPN2 (0.43) NPC1RAB9APTPN1PTPN2PTPN6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140243334-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-28 US disclosed
WO-2012012320-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENIUM PHARMACEUTICALS, INC. (US) 2012-01-26 WO disclosed
US-20120015942-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-01-19 US disclosed
US-20120015942-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-01-19 US disclosed
US-20120015942-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015942-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC2 NPC1 2892/4885RAB9A 1979/4885PTPN1 3390/4885
US-20140243334-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF HDAC6, H1-3, H1-5 NPC1 3030/4885RAB9A 939/4885PTPN1 3540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.